Nexcelom’s CTO on the Future of CAR T Workflow
Nexcelom founder and CTO, Dr. Jean Qiu, describes 3 major reasons why we partner with global and local research organizations to streamline CAR-T workflow.
Advantages of a Standardized Automated Cell Counting Method for Cell Therapy
Q & A regarding the crucial need for accurate and consistent cell counting methods for development and manufacturing of CAR-T under GMP/GLP conditions.